Early results of prostate cancer radiation therapy: An analysis with emphasis on research strategies to improve treatment delivery and outcomes

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Yamoah, Kosj ^a,c   Beecham, Kwamena ^b   Hegarty, Sarah E ^a   Hyslop, Terry ^a   Showalter, Timothy ^a   Yarney, Joel ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF GHANA   (Ghana)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

African men; Biochemical failure; External beam RT; Prostate cancer

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; FREEDOM FROM BIOCHEMICAL FAILURE; GHANA; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PROSTATE CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DOSE FRACTIONATION; GHANA; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872173859     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-23     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in, GLOBOCAN 2008. Int J Cancer 2008, 127(12):2893-2917.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61(6):1079-1092. 10.1016/j.eururo.2012.02.054, 22424666.
3. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, Parkin DM. Cancer burden in Africa and opportunities for prevention. Cancer 2012, 118(18):4372-4384. 10.1002/cncr.27410, 22252462.
4. Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Pract 1995, 3(1):19-30.
5. Underwood SM. Reducing the burden of cancer borne by African Americans: if not now, when?. Cancer Epidemiol Biomarkers Prev 2003, 12(3):270s-276s.
6. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011, 43(6):570-573. 10.1038/ng.839, 3102788, 21602798.
7. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000, 68(1):82-91. 10.1067/mcp.2000.108506, 10945319.
8. Powell IJ, Land SJ, Dey J, Heilbrun LK, Hughes MR, Sakr W, Everson RB. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 2005, 103(3):528-537. 10.1002/cncr.20788, 15630701.
9. Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology group. J Natl Cancer Inst 2009, 101(14):984-992. 10.1093/jnci/djp175, 2724852, 19584328.
10. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001, 93(3):219-225. 10.1093/jnci/93.3.219, 11158191.
11. Fowler JE, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol 1996, 156(1):133-136. 10.1016/S0022-5347(01)65966-4, 8648774.
12. Roach M, Krall J, Keller JW, Perez CA, Sause WT, Doggett RL, Rotman M, Russ H, Pilepich MV, Asbell SO, et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys 1992, 24(3):441-449. 10.1016/0360-3016(92)91058-U, 1399729.
13. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst 1998, 90(13):986-990. 10.1093/jnci/90.13.986, 9665146.
14. Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 2011, 117(24):5589-5600. 10.1002/cncr.26183, 21692058.
15. Odedina FT, Ogunbiyi JO, Ukoli FA. Roots of prostate cancer in African-American men. J Natl Med Assoc 2006, 98(4):539-543. 2569237, 16623066.
16. Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 2009, 4(Suppl 1):S2. 10.1186/1750-9378-4-S1-S2, 2638461, 19208207.
17. Klufio GO. A review of genitourinary cancers at the Korle-Bu teaching hospital Accra, Ghana. West Afr J Med 2004, 23(2):131-134.
18. Wiredu EK, Armah HB. Cancer mortality patterns in Ghana: a 10-year review of autopsies and hospital mortality. BMC Public Health 2006, 6:159. 10.1186/1471-2458-6-159, 1539002, 16787544.
19. Yarney J, Vanderpuye V, Mensah J. Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men. Urol Oncol 2011, Mar 25. [Epub ahead of print-10.1016/j.urolonc.2011.01.018].
20. Gueye SM, Zeigler-Johnson CM, Friebel T, Spangler E, Jalloh M, MacBride S, Malkowicz SB, Rebbeck TR. Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men. Urology 2003, 61(5):987-992. 10.1016/S0090-4295(02)02588-8, 12736021.
21. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239. 10.1001/jama.294.10.1233, 16160131.
22. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474. 10.1245/s10434-010-0985-4, 20180029.
23. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010, 8(2):145.
24. Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 2011, 117(24):5589-5600. 10.1002/cncr.26183, 21692058.
25. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003, 21(21):3972-3978. 10.1200/JCO.2003.11.023, 14581419.
26. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65(4):965-974. 10.1016/j.ijrobp.2006.04.029, 16798415.
27. Reeler AV, Mellstedt H. Cancer in developing countries: challenges and solutions. Ann Oncol 2006, 17(Suppl 8):viii7-viii8.
28. Mellstedt H. Cancer initiatives in developing countries. Ann Oncol 2006, 17(Suppl 8):viii24-viii31.
29. Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. J Natl Med Assoc 2002, 94(7):619-627. 2594316, 12126288.
30. Udeh FN. Prostatic carcinoma in Nigeria: a 10-year retrospective study. Int Urol Nephrol 1981, 13(2):159-166. 10.1007/BF02082060, 7327891.
31. Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc 1999, 91(3):159-164. 2608450, 10203918.
32. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365(2):107-118. 10.1056/NEJMoa1012348, 21751904.
33. Sohayda CJ, Kupelian PA, Altsman KA, Klein EA. Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol 1999, 162(4):1331-1336. 10.1016/S0022-5347(05)68279-1, 10492191.
34. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280(11):969-974. 10.1001/jama.280.11.969, 9749478.
35. Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force 2011, Rockville (MD): Agency for Healthcare Research and Quality (US), Report No.: 12-05160-EF-1.
36. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009, 56(4):584-591. 10.1016/j.eururo.2009.07.018, 19660851.
37. Studer UE, Collette L. What can be concluded from the ERSPC and PLCO trial data?. Urol Oncol 2010, 28(6):668-669. 10.1016/j.urolonc.2010.03.011, 21062648.
38. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29(15):2020-2026. 10.1200/JCO.2010.31.4377, 3138546, 21464418.
39. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26(15):2497-2504. 10.1200/JCO.2007.14.9021, 18413638.
40. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106. 10.1016/S0140-6736(02)09408-4, 12126818.
41. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61(5):1285-1290. 10.1016/j.ijrobp.2004.08.047, 15817329.